Enduru N, Fernandes B, Zhao Z
Front Genet. 2024; 15():1376050.
PMID: 38706793
PMC: 11069310.
DOI: 10.3389/fgene.2024.1376050.
Yu H, Gao Y, He T, Li M, Zhang Y, Zheng J
Front Cell Dev Biol. 2022; 10:818141.
PMID: 36506101
PMC: 9729784.
DOI: 10.3389/fcell.2022.818141.
Vandael D, Gounko N
Transl Psychiatry. 2019; 9(1):272.
PMID: 31641098
PMC: 6805916.
DOI: 10.1038/s41398-019-0581-8.
Ishii M, Iadecola C
Cell Metab. 2015; 22(5):761-76.
PMID: 26365177
PMC: 4654127.
DOI: 10.1016/j.cmet.2015.08.016.
Sztainberg Y, Kuperman Y, Justice N, Chen A
J Neurosci. 2011; 31(48):17416-24.
PMID: 22131403
PMC: 6623832.
DOI: 10.1523/JNEUROSCI.3087-11.2011.
The role of G protein-coupled receptors in the pathology of Alzheimer's disease.
Thathiah A, De Strooper B
Nat Rev Neurosci. 2011; 12(2):73-87.
PMID: 21248787
DOI: 10.1038/nrn2977.
Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.
Chapter M, White C, DeRidder A, Chadwick W, Martin B, Maudsley S
Pharmacol Ther. 2009; 125(1):39-54.
PMID: 19686775
PMC: 2815023.
DOI: 10.1016/j.pharmthera.2009.07.006.
Effects of stress and stress hormones on amyloid-beta protein and plaque deposition.
Dong H, Csernansky J
J Alzheimers Dis. 2009; 18(2):459-69.
PMID: 19584430
PMC: 2905685.
DOI: 10.3233/JAD-2009-1152.
Synaptic physiology of central CRH system.
Gallagher J, Orozco-Cabal L, Liu J, Shinnick-Gallagher P
Eur J Pharmacol. 2008; 583(2-3):215-25.
PMID: 18342852
PMC: 2424315.
DOI: 10.1016/j.ejphar.2007.11.075.
Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.
Horgan J, Miguel-Hidalgo J, Thrasher M, Bissette G
J Alzheimers Dis. 2007; 12(2):115-27.
PMID: 17917156
PMC: 2919580.
DOI: 10.3233/jad-2007-12201.
Class II G protein-coupled receptors and their ligands in neuronal function and protection.
Martin B, Lopez de Maturana R, Brenneman R, Walent T, Mattson M, Maudsley S
Neuromolecular Med. 2005; 7(1-2):3-36.
PMID: 16052036
PMC: 2636744.
DOI: 10.1385/nmm:7:1-2:003.
Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas.
Refojo D, Echenique C, Muller M, Reul J, Deussing J, Wurst W
Proc Natl Acad Sci U S A. 2005; 102(17):6183-8.
PMID: 15833812
PMC: 1087957.
DOI: 10.1073/pnas.0502070102.
Involvement of dopaminergic processes in the striatum during the effects of corticoliberin on the behavior of active and passive rats.
Shalyapina V, Rakitskaya V, Rodionov G
Neurosci Behav Physiol. 2003; 33(6):629-33.
PMID: 14552557
DOI: 10.1023/a:1023995023491.
Infantile spasms: hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists.
Baram T, Mitchell W, Brunson K, Haden E
Dev Neurosci. 1999; 21(3-5):281-9.
PMID: 10575251
PMC: 3139473.
DOI: 10.1159/000017407.
Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.
Lehnert H, Schulz C, Dieterich K
Neurochem Res. 1998; 23(8):1039-52.
PMID: 9704593
DOI: 10.1023/a:1020751817723.
Inhibition of pituitary-adrenal secretion by a corticotropin releasing hormone antagonist in humans.
Baram T, Mitchell W, Haden E
Mol Psychiatry. 1996; 1(4):320-4.
PMID: 9118358
PMC: 3399691.
Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.
Quirion R
J Psychiatry Neurosci. 1993; 18(5):226-34.
PMID: 8297921
PMC: 1188543.
Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.
Leake A, Ferrier I
Drugs Aging. 1993; 3(5):408-27.
PMID: 8241606
DOI: 10.2165/00002512-199303050-00003.
Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy.
Slotkin T, Seidler F, Crain B, Bell J, Bissette G, Nemeroff C
Proc Natl Acad Sci U S A. 1990; 87(7):2452-5.
PMID: 2320567
PMC: 53707.
DOI: 10.1073/pnas.87.7.2452.